A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

NCT07710157 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Medical University Innsbruck

Collaborators